AKT-MP: Access to Kidney Transplantation in Minority Populations

Sponsor
University of New Mexico (Other)
Overall Status
Recruiting
CT.gov ID
NCT04615819
Collaborator
Case Western Reserve University (Other), University of Massachusetts, Amherst (Other), University of Pittsburgh (Other)
398
1
2
45.7
8.7

Study Details

Study Description

Brief Summary

Hispanic/Latino (HL) and American Indian (AI) patients are more likely than whites to have kidney failure, but less likely to complete transplant evaluation or receive a kidney transplant (KT), the best treatment for kidney failure. Using comparative effectiveness research methods, we will conduct a pragmatic randomized trial to compare the efficacy and cost- effectiveness of two approaches to help HL and AI patients overcome barriers to completing transplant evaluation and receiving a KT: a streamlined KT evaluation process and a peer-assisted evaluation program; and, we will determine best practices to assist other transplant centers in implementing the better program. Findings from this work may help reduce disparities in transplant evaluation and KT.

Condition or Disease Intervention/Treatment Phase
  • Other: Kidney Transplant Fast Track (KTFT)
  • Other: Peer Navigation (PN)
N/A

Detailed Description

The AKT-MP study will assess whether Kidney Transplant Fast Track (KTFT), a streamlined KT evaluation process, or peer navigators (PN) who were former KT patients to help patients "navigate" their way through KT evaluation, can help vulnerable patients with kidney failure overcome barriers to transplant listing. After culturally and contextually adapting the two interventions, we will use a comparative effectiveness (CER) approach to conduct a pragmatic randomized trial of 398 kidney failure patients to compare the efficacy and effectiveness of the two approaches in disadvantaged groups at a university-affiliated transplant center with large HL and AI kidney failure patient populations, and we will compare results to historic comparison populations (local and national). We will assess facilitators and barriers to widespread implementation and conduct a cost effectiveness analysis. Although it is expected that KTFT will be more effective than PN, KTFT may also be more costly, requiring significant administrative and clinical changes in the transplant center, which may be impractical to maintain. Further, KTFT may lead to more patient ambivalence because the shortened evaluation period will give them less time to consider their treatment options. Thus, an important aspect of the proposed study is to comparative the effectiveness of the two methods. Ultimately, our study will inform transplant programs faced with disparities in KT about which disparity-reducing intervention to use given their particular needs and resources.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
398 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Access to Kidney Transplantation in Minority Populations (AKT-MP)
Actual Study Start Date :
Jan 11, 2022
Anticipated Primary Completion Date :
Nov 1, 2025
Anticipated Study Completion Date :
Nov 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Arm 1

KTFT

Other: Kidney Transplant Fast Track (KTFT)
Streamlined KT evaluation involving completion of most or all testing on the same day a patient arrives for their first pre-transplant clinic appointment. Or, a transplant clinic scheduler secures testing within a 4 week period.

Experimental: Arm 2

PN

Other: Peer Navigation (PN)
Uses trained, previous KT recipients who meet weekly to monthly with patient participants to provide tailored information and assistance in completing the necessary steps to proceed to transplant.

Outcome Measures

Primary Outcome Measures

  1. Rate of KT evaluation completion [Through study completion, an average of 1 year]

    Completion of evaluation for KT and placement on the transplant waiting list.

Secondary Outcome Measures

  1. KT ambivalence [Through study completion, an average of 1 year]

    KT ambivalence will be assessed with the Decisional Conflict Scale, with questions rating from strongly agree to strongly disagree.

  2. Patient Reported Quality of Life [Through study completion, an average of 1 year]

    We will use the PROMIS Scale v1.2 Global Health measure to assess quality of life (QOL), which includes items relevant to patients with kidney disease, including overall health, physical limitations, work, pain, energy, and emotional problems.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Undergoing kidney transplant evaluation at the University of New Mexico

  • Greater than or equal to 18 years of age

  • Mentally competent

Exclusion Criteria:
  • Children less than 18 years of age are excluded because all research-related measurements are designed for patients over the age of 18. Children less than 18 years of age have dissimilar decision-making authority as a result of their developmental stage and dependency on adult guardians who must make all their transplant-related decisions, as required by all pediatric transplant centers. The proposed study focuses only on adult transplant patients.

  • Waitlisted at another transplant center

  • Prior kidney transplant

  • Incarcerated patients

  • Pregnant women

  • Active systemic infection

  • Non-skin malignancy or melanoma in the past 2 years

  • Known cognitive impairment

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of New Mexico Albuquerque New Mexico United States 87131

Sponsors and Collaborators

  • University of New Mexico
  • Case Western Reserve University
  • University of Massachusetts, Amherst
  • University of Pittsburgh

Investigators

  • Principal Investigator: Larissa Myaskovsky, PhD, University of New Mexico

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Larrisa Myaskovsky, Professor, University of New Mexico
ClinicalTrials.gov Identifier:
NCT04615819
Other Study ID Numbers:
  • 20-387 AKT-MP
First Posted:
Nov 4, 2020
Last Update Posted:
Jan 25, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Larrisa Myaskovsky, Professor, University of New Mexico
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 25, 2022